MiniMed to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
MiniMed (Nasdaq: MMED) announced that its management will join a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MiniMed (Nasdaq: MMED) announced that its management will join a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference.
The session is scheduled for Monday, June 8, 2026, at 11:20 a.m. EDT, with a live webcast and replay available on the MiniMed investor relations website.
Details
News Market Reaction – MMED
On May 26, the day this news came out, MMED closed 5.81% below the previous close.
Data tracked by StockTitan Argus for the May 26 session.
Key Figures
- Conference edition
- 47th Annual
- Goldman Sachs Global Healthcare Conference
- Conference date
- June 8, 2026
- Scheduled fireside chat
- Chat time
- 11:20 a.m. EDT
- Start time of MiniMed fireside chat
Historical Context
-
Randomized trial showed strong glycemic outcomes across sensors with 780G.
-
Announced schedule for Q4 and full-year 2026 financial results release.
-
FDA cleared MiniMed Flex™, a smaller smartphone-controlled insulin pump.
-
Closed IPO of 28,000,000 shares at $20.00, raising ~$538M in proceeds.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The fireside chat will take place on Monday, June 8, 2026, at 11:20 a.m. EDT.
A live webcast and replay will be accessible on the MiniMed Investor Relations website: investors.minimed.com/events.
About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in more than 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.
Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
View original content to download multimedia:https://www.prnewswire.com/news-releases/minimed-to-participate-in-goldman-sachs-47th-annual-global-healthcare-conference-302780816.html
SOURCE MiniMed
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.